Description: Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments. The company offers products in various therapeutic areas, including liver disease treatments, such as Levovir and Legalon; diabetic complication products comprising Dexid and Thioctacid; CNS disorder drugs consisting of Lonasen, Ixel, and Orfil; and respiratory disease treatments, which comprise Azeptin and Asima. It also provides OTC products; toothpastes, and hair and skin care goods; and nutritional supplements. In addition, the company offers products for antihistamines, hepatitis and gastrointestinal, sedative and antidote, anti-cancer, thyroid and osteoporosis, diabetes, obstetrics, urinogenital, cardiovascular, dermatology, obesity, pain relief, and muscle relaxant. Further, it provides products for bruises, skin and mucous membrane, rhinitis, cold symptoms, cough, phlegm and asthma, rheumatoid arthritis, osteoarthritis, pain caused by cold and fever, dysmenorrhea, NSAIDs, inflammation, joint inflammation, tinea pedis, infected wounds, dermatitis, antivirals-herpes, eczema, diarrhea, dyspepsia, sense of distension, anti-histamine, anti-ulcer, constipation, anemia, pregnant multivitamins, candidiasis, athlete's foot, onychomycosis, stomatitis, pimple, acne, physical fatigue, neuralgia, myalgia, and arthralgia. Additionally, the company offers medicines for period of lactation, rickets, night blindness, varicose vein, and sputum; and quasi drugs and medical devices, as well as health functional food. It also develops anti-diabetes compound with Melior Pharmaceuticals; and anti-cancer drugs with LSK BioPartners, as well as cell therapies using adult stem cells, as well as holds a license for a novel candidate to treat movement disorder in Parkinson's disease patients. The company was founded in 1960 and is based in Seoul, South Korea.
Home Page: www.bukwang.co.kr
7, Sangdo-ro
Seoul,
06955
South Korea
Phone:
82 2 828 8114
Officers
| Name | Title |
|---|---|
| Sung-Gu Lee | Chief Exec. Officer, Pres and Director |
| Ms. Yoo Hui-Won | Chief Exec. Officer and Representative Director |
| Tae-Hyun Kim | VP and Director |
| Won-Tae Park | Managing Director and Director |
| Il-Tae Kim | Managing Director |
| Young-Choon Lee | Managing Director |
| Geum-Seo Gu | Managing Director |
| Jong-Moon Kim | Managing Director |
| Mr. Sang-Hoon Kim | Sr. Managing Director, Head of Planning Adjustment Department and Representative Director |
| Hee-Sang Lee | Managing Director |
Exchange: KO
Country: KR
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.451 |
| Price-to-Sales TTM: | 3.5502 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 568 |